Green Cross Corp (KO:006280) — Market Cap & Net Worth
Market Cap & Net Worth: Green Cross Corp (006280)
Green Cross Corp (KO:006280) has a market capitalization of $946.71 Million (₩1.40 Trillion) as of September 18, 2026. Listed on the KO stock exchange, this Korea-based company holds position #9164 globally and #239 in its home market, demonstrating a -3.62% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Green Cross Corp's stock price ₩122400.00 by its total outstanding shares 11413178 (11.41 Million). Also see 006280 total assets for a full breakdown of the balance sheet.
Green Cross Corp Market Cap History: 2015 to 2026
Green Cross Corp's market capitalization history from 2015 to 2026. Data shows change from $1.34 Billion to $946.71 Million (-2.68% CAGR). Also see Green Cross Corp (006280) cash conversion ratio for how efficiently the company converts equity into cash flow.
Green Cross Corp Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Green Cross Corp's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Green Cross Corp (006280) stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.00x
Green Cross Corp's market cap is 0.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $1.34 Billion | $1.05 Trillion | $94.97 Billion | 0.00x | 0.01x |
| 2016 | $1.16 Billion | $1.20 Trillion | $62.97 Billion | 0.00x | 0.02x |
| 2017 | $1.67 Billion | $1.29 Trillion | $53.25 Billion | 0.00x | 0.03x |
| 2018 | $1.02 Billion | $1.33 Trillion | $34.43 Billion | 0.00x | 0.03x |
| 2019 | $996.58 Million | $1.37 Trillion | -$3.64 Billion | 0.00x | N/A |
| 2020 | $3.07 Billion | $1.50 Trillion | $81.05 Billion | 0.00x | 0.04x |
| 2021 | $1.66 Billion | $1.54 Trillion | $123.21 Billion | 0.00x | 0.01x |
| 2022 | $1.00 Billion | $1.71 Trillion | $65.45 Billion | 0.00x | 0.02x |
| 2023 | $970.69 Million | $1.63 Trillion | -$26.63 Billion | 0.00x | N/A |
| 2024 | $1.39 Billion | $1.68 Trillion | -$26.28 Billion | 0.00x | N/A |
Competitor Companies of 006280 by Market Capitalization
Companies near Green Cross Corp in the global market cap rankings as of September 18, 2026. Review how tangible is Green Cross Corp's equity to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Green Cross Corp by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #519 globally with a market cap of $52.60 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #633 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #640 globally with a market cap of $43.16 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #670 globally with a market cap of $40.62 Billion USD ( CN¥277.61 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #519 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #633 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €16.00 |
| #640 | GALDERMA GROUP AG | NYSE:GALDY | $43.16 Billion | $37.02 |
| #670 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $40.62 Billion | CN¥43.52 |
Green Cross Corp Historical Marketcap From 2015 to 2026
Between 2015 and today, Green Cross Corp's market cap moved from $1.34 Billion to $ 946.71 Million, with a yearly change of -2.68%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩946.71 Million | -23.02% |
| 2025 | ₩1.23 Billion | -11.42% |
| 2024 | ₩1.39 Billion | +43.03% |
| 2023 | ₩970.69 Million | -3.09% |
| 2022 | ₩1.00 Billion | -39.72% |
| 2021 | ₩1.66 Billion | -45.82% |
| 2020 | ₩3.07 Billion | +207.72% |
| 2019 | ₩996.58 Million | -1.82% |
| 2018 | ₩1.02 Billion | -39.37% |
| 2017 | ₩1.67 Billion | +44.76% |
| 2016 | ₩1.16 Billion | -13.52% |
| 2015 | ₩1.34 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 17th, 2026 the market cap of Green Cross Corp was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $946.71 Million USD |
| MoneyControl | $946.71 Million USD |
| MarketWatch | $946.71 Million USD |
| marketcap.company | $946.71 Million USD |
| Reuters | $946.71 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Green Cross Corp
GC Biopharma Corp., a biopharmaceutical company, develops and sells pharmaceutical drugs in South Korea and internationally. It provides over-the-counter drugs, such as Acustop Cataplasma for Analgesic and anti-inflammatory effect; Kenhancer plaster for anti-inflammatory; and Zenol Cool Type and Zenol Mild Hot Type drugs to treat anti-inflammatory and pain relief. The company also offers Albumin-… Read more